By using this site, you agree to the Privacy Policy and Terms Of Use.
Accept
WhatsNew2DayWhatsNew2Day
  • Home
  • Australia
  • Business
  • Economy
  • Entertainment
  • Gaming
  • Health
  • Lifestyle
  • Science
  • Sports
  • Tech
  • US
  • World
Reading: Scientists develop genetic test to see if blood cancer drugs will work
Share
Aa
WhatsNew2DayWhatsNew2Day
Aa
  • Home
  • Contact
  • About us
  • Privacy Policy
  • Home
  • Australia
  • Business
  • Economy
  • Entertainment
  • Gaming
  • Health
  • Lifestyle
  • Science
  • Sports
  • Tech
  • US
  • World
Follow US
© 2022 WhatsNew2Day News Network. All Rights Reserved.
WhatsNew2Day > US > Scientists develop genetic test to see if blood cancer drugs will work
US

Scientists develop genetic test to see if blood cancer drugs will work

Last updated: 2023/03/18 at 6:22 PM
Jacky 2 days ago
Share
Scientists have developed a test to identify which blood cancer patients will benefit most from a drug that can prevent their cancer from coming back (file photo)
SHARE

Scientists have developed a test to identify which blood cancer patients will benefit most from a drug that can prevent their cancer from coming back. The test, which looks for genetic clues in cancer cells, can identify the 10 percent of patients who see little effect from the lifesaving lenalidomide.

This could save them unnecessary side effects such as exhaustion, infections and an increased risk of other cancers, although experts need more data before they know if it’s safe to stop using the drug.

But it also helps identify patients who may need drugs other than lenalidomide, and reassures those most likely to benefit.

The test is so useful that experts call for it to be used to guide the treatment of the 6,000 Britons diagnosed with myeloma, a type of blood cancer, each year.

Many myeloma patients take lenalidomide for up to a decade to try to keep the disease under control.

Scientists have developed a test to identify which blood cancer patients will benefit most from a drug that can prevent their cancer from coming back (file photo)

“For most, the drug is well tolerated, but some experience side effects such as feeling tired or being prone to infection,” says Dr. Martin Kaiser, a consultant haematologist and clinical scientist at the Institute for Cancer Research London.

“Some take it for up to a decade. A common question they ask is ‘Do I really have to keep taking this medication?’ and ‘How much is it really helping me?’ ‘

Some studies have shown that taking the drug for a long time may be associated with an increased risk of some types of cancer, including Hodgkin lymphoma. Myeloma affects a type of blood cells called plasma cells that help fight infection and are made in the bone marrow, the spongy tissue in the center of bones.

It causes plasma cells to multiply excessively, leading to a buildup of defective cells in the bone marrow, which can damage the bones.

This also disrupts the production of other blood cells, preventing the body from effectively fighting infection. The disease is sometimes called multiple myeloma because it affects the bone marrow in several areas, such as the spine and ribs.

To treat myeloma, chemotherapy and steroids are given to kill the defective cells, but the vast majority of patients will see the disease return within a few years.

Lenalidomide blocks the growth of abnormal cells, keeping cancer at bay for about three years on average, compared to two years without treatment. “But there is a wide variation: for some it is a decade, for others a year,” says Professor Kaiser.

Previously, there was no way of knowing who would not respond to the drug. But the study has identified a group of ‘super responders’, who are 40 times more likely to have their cancer stop growing than others.

In the study, researchers from the Institute for Cancer Research and the University of Leeds performed the new test on 556 newly diagnosed myeloma patients. It involves taking a sample of bone marrow tissue through a needle in the back, under local anesthesia, and looking for patterns in the cancer’s DNA.

The scientists found that a third of patients with a particular pattern lived an average of just under five years on lenalidomide, compared with an average of around three. Meanwhile, about one in 10 with another genetic pattern did not benefit as much, with results similar to those not taking lenalidomide.

“We are testing new drug combinations for this group that are proving beneficial,” says Dr. Kaiser. “Those who are not as likely to benefit may consider options such as clinical trials that test new drug combinations.”

The test, which looks for genetic clues in cancer cells, can identify the 10 percent of patients who see little effect from the lifesaving lenalidomide.  This could save them from unnecessary side effects, such as exhaustion, infections and an increased risk of other cancers (file photo)

The test, which looks for genetic clues in cancer cells, can identify the 10 percent of patients who see little effect from the lifesaving lenalidomide. This could save them from unnecessary side effects, such as exhaustion, infections and an increased risk of other cancers (file photo)

Experts say it would be feasible to use the test in this way, because it is already widely available on the NHS. “Many specialists use it after diagnosis to give patients an idea of ​​how aggressive the cancer is,” says Professor Kaiser. “It helps us better advise patients when it comes to their treatment.”

Cecelia Brunott, 46, from Surrey, was diagnosed with myeloma in 2020 and has been taking lenalidomide since September 2021, following a bone marrow transplant.

She volunteered to be tested and the results showed that her cancer was not genetically high risk.

“My cancer protein levels have dropped since taking lenalidomide and are no longer measurable,” he says. “The trial has given me the peace of mind that the drug is helping to keep cancer away for as long as possible.”

You Might Also Like

Chelsea teacher Jane Edwards accused of grooming a teenager at QLD school in Indooroopilly

How coffee could reduce the risk of skin cancer: The Gut Health Guru DR MEGAN ROSSI

Emmerdale SPOILER: Samson gets caught for his blackmail plot

Pasquale Lanciana, mastermind behind $2.3 million Armaguard van heist, launches appeal

The Science That Proves Grief Can Harm Both Your Body And Mind

TAGGED: blood, cancer, dailymail, develop, drugs, Genetic, health.., NHS, scientists, test, work
Jacky March 18, 2023
Share this Article
Facebook Twitter Email Print
Share
Previous Article Battered central California braces for next storm starting Monday Battered central California braces for next storm starting Monday
Next Article Kind: Joe Jonas stopped to help a fan who had fallen to the ground in New York after performing at Marquis Theater Joe Jonas stops to help a fan fallen to the ground after performing a sold-out concert in New York

Latest

RVH auxiliary nears $2.5M halfway point for NICU expansion fundraiser
RVH auxiliary nears $2.5M halfway point for NICU expansion fundraiser
News
San Francisco Bay area to phase out natural gas heating appliances
San Francisco Bay area to phase out natural gas heating appliances
News
Chelsea Jane Edwards, 28, (pictured), from Paradise Point, south-east Brisbane, was charged with two counts of grooming and one count of indecent treatment of a child under 16 while working at Indooroopilly State School on March 10th.
Chelsea teacher Jane Edwards accused of grooming a teenager at QLD school in Indooroopilly
News
Crush Test Anxiety: The Ultimate Guide to Maximize Your Performance!
Crush Test Anxiety: The Ultimate Guide to Maximize Your Performance!
News
Public sector strike | Is wage agreement imminent?
Public sector strike | Is wage agreement imminent?
News
Kia Hopes to Jump-start China Business with New EV
Kia Hopes to Jump-start China Business with New EV
Gaming

nba 2k23 mt

© WhatsNew2Day News Network. All Rights Reserved. Email: contact@whatsnew2day.com

  • Home
  • Contact
  • About us
  • Privacy Policy

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?